Clinical Trials

274 enrolled

Breast Neoplasms

NCT05806671 2023-04-10

Dalpiciclib Plus Fulvestrant With Pyrotinib in Hormone Receptor-positive, HER2-low Advanced Breast Cancer That Progressed on Previous CDK4/6i Plus AI Therapy

30 enrolled

Breast Neoplasms

NCT05792410 2023-03-31

A Phase Ⅰb/Ⅱ Clinical Study of SHR-A1811 Combined With Other Therapies in Patients With HER2 Low Advanced or Metastatic Breast Cancer.

Phase 1/2 Unknown

300 enrolled

Breast Neoplasms

NCT03772353 2023-03-07

PLEASURABLE

Phase 1/2 Unknown

59 enrolled

Breast Neoplasms

NCT02983071 2023-02-15

G1T38, a CDK 4/6 Inhibitor, in Combination With Fulvestrant in Hormone Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer

Phase 1/2 Unknown

102 enrolled

Breast Neoplasms, Carcinoma, Ductal, Breast

NCT05411380 2022-11-04

Tucidinostat Combined With Metronomic Capecitabine and Endocrine Therapy for Advanced HR-positive, HER2-negative Breast Cancer After CDK4/6 Inhibitor.

73 enrolled

Breast Neoplasms

NCT05577923 2022-10-13

Exploring Whether Disease-free Intervals Can Guide Endocrine Combined Targeted Therapy for ER+/HER2+ Advanced Breast Cancer (T-sunflower)

126 enrolled

Breast Neoplasms

NCT05186545 2022-09-02

An Exploratory Study of Surufatinib Combined With Chidamide and Fulvestrant in HR Positive Unresectable Metastatic Breast Cancer

63 enrolled

Breast Neoplasms

NCT05504213 2022-08-17

A Phase Ib Study of HS-10352 Plus Fulvestrant in Patients With Advanced Breast Cancer

Phase 1 Unknown

224 enrolled

Breast Neoplasms

NCT04334330 2022-05-02

Palbociclib, Trastuzumab,Pyrotinib and Fulvestrant Treatment in Patients With Brain Metastasis From ER/PR Positive, HER-2 Positive Breast Cancer: A Multi-center, Prospective Study in China

34 enrolled

BreastCNS

Brain Neoplasms, Breast Neoplasms

NCT02909361 2022-04-20

Fulvestrant 500mg in Patients With Advanced Breast Cancer

Unknown

500 enrolled

Breast Neoplasms

NCT02626507 2022-02-09

Phase I Study of Combination of Gedatolisib With Palbociclib and Faslodex in Patients With ER+/HER2- Breast Cancer

Phase 1 Unknown

18 enrolled

Breast Neoplasms

NCT04936295 2021-06-23

Fulvestrant Plus Anlotinib in HR(+)/HER2(-) Metastatic Breast Cancer With FGFR Mutation

61 enrolled

Breast Neoplasms

NCT04852081 2021-04-21

Analysis of Therapy Sequence in Women With HR+, HER2 - mBC in Moscow: A Multicenter Retrospective Observational Study.

Unknown

1,000 enrolled

Breast Neoplasms

NCT04034589 2020-12-22

Pyrotinib in Combination With Fulvestrant in Patients With HER2 Positive，HR-Positive Metastatic Breast Cancer

46 enrolled

Breast Neoplasms

NCT04289974 2020-02-28

Predicted Biomarkers of CDK4/6 Inhibitors (Palbociclib) in ER-positive Metastasis Breast Cancer

Unknown

100 enrolled

Breast Neoplasms

NCT02690480 2020-02-05

FLIPPER

189 enrolled

Breast Neoplasms, Neoplasm Metastasis

NCT03024580 2019-08-15

MEGA

20 enrolled

Breast Neoplasms

NCT04033172 2019-07-25

Pyrotinib

40 enrolled

Breast Neoplasms

NCT03591549 2018-07-23

Fulvestrant in Metastatic Breast Cancer

Phase 4 Unknown

30 enrolled

Breast Neoplasms

NCT02000193 2018-07-10

FANCY

58 enrolled

Breast Neoplasms

NCT03560856 2018-06-18

PALPETBIO

54 enrolled

Breast Neoplasms, Neoplasm Metastasis

NCT03202862 2017-06-29

The Efficacy of Fulvestrant in ESR1(Estrogen Receptor 1) Mutated Metastatic Breast Cancer

50 enrolled

Breast Neoplasms

NCT01266213 2017-05-01

FLAG

147 enrolled

Breast Neoplasms

NCT02646735 2017-01-02

FRIEND

148 enrolled

Breast Neoplasms

NCT02383030 2016-06-15

FUMANCE

156 enrolled

Breast Neoplasms, Neoplasm Metastasis

NCT02394496 2016-06-15

OVER

396 enrolled

Breast Neoplasms

NCT02404051 2016-06-15

FEVEX

745 enrolled

Breast Neoplasms, Neoplasm Metastasis

NCT02072512 2014-02-26

PROOF

180 enrolled

Breast Neoplasms

NCT00688194 2013-08-26

Fulvestrant With or Without Lapatinib and/or Aromatase Inhibitor Therapy in Treating Postmenopausal Women With Metastatic Breast Cancer That Progressed After Previous Aromatase Inhibitor Therapy

396 enrolled

Breast Neoplasms

NCT00927511 2011-07-22

FIDeS

104 enrolled